Cabozantinib as a second-line treatment option in hepatocellular carcinoma

Alberto D’Angelo, Navid Sobhani, Stefan Bagby, Andrea Casadei-Gardini, Giandomenico Roviello

Research output: Contribution to journalReview articlepeer-review

12 Citations (SciVal)
131 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Cabozantinib as a second-line treatment option in hepatocellular carcinoma'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science